Vigilant Capital Management’s United Therapeutics UTHR Stock Holding History

Vigilant Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$141K	Hold	639	–	–	0.01%	180
2023 Q1	$143K	Hold	639	–	–	0.01%	172
2022 Q4	$178K	Hold	639	–	–	0.02%	154
2022 Q3	$134K	Hold	639	–	–	0.01%	187
2022 Q2	$151K	Hold	639	–	–	0.01%	177
2022 Q1	$115K	Hold	639	–	–	0.01%	226
2021 Q4	$138K	Hold	639	–	–	0.01%	231
2021 Q3	$118K	Hold	639	–	–	0.01%	193
2021 Q2	$115K	Hold	639	–	–	0.01%	196
2021 Q1	$107K	Buy	+639	New	+$107K	0.01%	189

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vigilant Capital Management's UTHR Position: Q2 2023 in Review

Vigilant Capital Management held its United Therapeutics (UTHR) position steady in Q2 2023 at 639 shares worth $141K. The position accounts for 0.01% of the portfolio, ranked #180.

Vigilant Capital Management first reported a position in UTHR in Q1 2021 and has held it in 10 quarters since. The position peaked at $178K in Q4 2022. 475 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Vigilant Capital Management held 639 shares of United Therapeutics worth $141K as of Q2 2023.
Vigilant Capital Management left its United Therapeutics share count unchanged in Q2 2023.
United Therapeutics made up 0.01% of Vigilant Capital Management's portfolio in Q2 2023, its #180 holding.
Vigilant Capital Management first reported a position in United Therapeutics in Q1 2021 and has held it in 10 quarters since.
Vigilant Capital Management's United Therapeutics position peaked at $178K in Q4 2022.
475 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.